Komipharm International Co., Ltd. announced that it has received KRW 10 billion in funding from W Asset Management Co., Ltd., Susung Asset Management Co., Ltd., Focus Asset Management Co., Ltd., DB Financial Investment Co.,Ltd., Investment Arm
June 04, 2018
Share
On June 4, 2018, Komipharm International Co., Ltd. (KOSDAQ:A041960) closed the transaction.
Komipharm International Co Ltd is a Korea-based company principally engaged in the development and manufacture of veterinary vaccines and veterinary pharmaceuticals. The Companyâs main products include veterinary vaccines such as total vaccines of respiratory disease for swine, vaccines of anthrax disease and black leg for cattle, vaccines for infectious bronchitis and Newcastle disease, and canine respiratory infection killed vaccines, and veterinary pharmaceuticals such as antibiotics, nutrients, disinfectants and others, which are used to treat pneumonia, pasteurellosis, enteritis, mastitis, swine erysipelas, septicemia, leptospirosis and bacterial diseases for livestock. The Company also engages in research and development of anticancer drugs and cancer pain-relieving agents. In addition, the Company provides services such as pathological biopsies, serum tests, and bacteria tests.
Komipharm International Co., Ltd. announced that it has received KRW 10 billion in funding from W Asset Management Co., Ltd., Susung Asset Management Co., Ltd., Focus Asset Management Co., Ltd., DB Financial Investment Co.,Ltd., Investment Arm
KOMIPHARM INTERNATIONAL CO., LTD. 
